Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Poisoning: Treatment Strategies

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...

Pathophysiology of Vomiting

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through interaction...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Prevention of Further Absorption of Poison

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature review.

Surgical neurology international·2026

Same author

Interprofessional collaborative practice: The model for cancer care.

Asia-Pacific journal of oncology nursing·2024

Same author

NCI's Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data.

Cancer research communications·2024

Same author

Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review.

World neurosurgery·2024

Same author

A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Same author

AONN+ Navigation Metrics That Support the Oncology Navigation Standards of Professional Practice.

Seminars in oncology nursing·2024

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Controlling emesis: evolving challenges, novel strategies.

Brenda Nevidjon¹, Rekha Chaudhary

¹Duke University School of Nursing, Durham, North Carolina 27710, USA. nevid001@mc.duke.edu

The Journal of Supportive Oncology

|September 28, 2010

Summary

This summary is machine-generated.

Novel antiemetic therapies improve control of chemotherapy-induced nausea and vomiting (CINV). Further research and new drug delivery systems aim to enhance patient quality of life and treatment compliance.

More Related Videos

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting

Published on: August 4, 2023

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

Related Experiment Videos

Last Updated: Jun 8, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting

Published on: August 4, 2023

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

Area of Science:

Oncology
Pharmacology
Patient Care

Background:

Chemotherapy, radiation therapy, and surgery can cause significant nausea and vomiting.
Despite advances, the severity of emesis is often underestimated, impacting quality of life, compliance, and treatment outcomes.
Effective antiemetic therapy is crucial for managing distressing side effects of cancer treatment.

Purpose of the Study:

To review recent advancements in antiemetic therapies.
To highlight the ongoing evolution of antiemetic strategies.
To emphasize the importance of managing chemotherapy-induced nausea and vomiting (CINV).

Main Methods:

Review of novel antiemetic agents, including 5-hydroxytryptamine and neurokinin-1 receptor antagonists.
Analysis of refined antiemetic therapeutic guidelines.
Exploration of risk factors for acute and delayed nausea and vomiting.
Consideration of nonpharmacologic complementary therapies.

Main Results:

Significant improvements in controlling nausea and vomiting have been achieved.
Novel therapies offer better tolerability and efficacy.
New oral drug delivery systems enhance convenience.

Conclusions:

Antiemetic therapy continues to evolve with new drug classes and improved guidelines.
Addressing inadequately controlled nausea and vomiting is essential for patient well-being and treatment adherence.
Future directions include further research into risk factors and complementary therapies, alongside innovative drug delivery systems.